Publications by authors named "Stephen D Shafran"

Claim this Profile
B
Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance.
Stephen D Shafran, Christine A Hughes

HIV Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying gaps in the treatment of hepatitis C in patients co-infected with HIV in Edmonton, Alberta.
Jessica M Round, Bohdan Savaryn, Sabrina S Plitt, Stephen D Shafran, Carmen L Charlton

Ann Hepatol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: "Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy".
Sergio M Borgia, Stephen D Shafran

J Hepatol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C direct-acting antiviral outcomes in patients 75 years and older.
Parmvir Parmar, Stephen D Shafran, Sergio M Borgia, Karen Doucette, Curtis L Cooper

JGH Open· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.
Alessandra Mangia, Scott Milligan, Mandana Khalili, Stefano Fagiuoli, Stephen D Shafran

Liver Int· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).
Fred Poordad, Mitchell L Shiffman, Wayne Ghesquiere, Alexander Wong, Gregory D Huhn, Stephen D Shafran

Antivir Ther· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
Sergio M Borgia, Janet Dearden, Eric M Yoshida, Stephen D Shafran, Ashley Brown

J Hepatol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection.
Tarik Asselah, Stephen D Shafran, Stefan Bourgeois, Ching-Lung Lai, Philippe Mathurin

J Viral Hepat· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of Shingles: Better Protection and Better Value With Recombinant Vaccine.
Stephen D Shafran

Ann Intern Med· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification.
Charlotte Hedskog, Bandita Parhy, Silvia Chang, Stefan Zeuzem, Christophe Moreno, Stephen D Shafran

Open Forum Infect Dis· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes.
Sergio M Borgia, Charlotte Hedskog, Bandita Parhy, Robert H Hyland, Luisa M Stamm, Stephen D Shafran

J Infect Dis· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
Christophe Hezode, Nancy Reau, Evguenia S Svarovskaia, Brian P Doehle, Ragavi Shanmugam, Stephen D Shafran

J Hepatol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Ira M Jacobson, Eric Lawitz, Edward J Gane, Bernard E Willems, Peter J Ruane, Stephen D Shafran

Gastroenterology· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
Jordan J Feld, Alnoor Ramji, Stephen D Shafran, Bernard Willems, Paul Marotta

Clin Infect Dis· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to: Comment on "Hepatitis C and the Sex Trade".
Stephen D Shafran

Can J Gastroenterol Hepatol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C and the sex trade.
Stephen D Shafran

Can J Gastroenterol Hepatol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Menard et al.
Stephen D Shafran

Clin Infect Dis· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing.
Stephen D Shafran

Can J Gastroenterol Hepatol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Jordan J Feld, Ira M Jacobson, Christophe Hézode, Tarik Asselah, Peter J Ruane, Stephen D Shafran

N Engl J Med· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials.
Stephen D Shafran

Clin Infect Dis· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.
Christophe Hézode, Gideon M Hirschfield, Wayne Ghesquiere, William Sievert, Maribel Rodriguez-Torres, Stephen D Shafran

Gut· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
Gregory J Dore, Eric Lawitz, Christophe Hézode, Stephen D Shafran, Alnoor Ramji

Gastroenterology· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial.
Mitchell L Shiffman, Hugo Cheinquer, Christoph P Berg, Thomas Berg, Cláudio de Figueiredo-Mendes, Stephen D Shafran

Hepatol Int· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating Clostridium difficile infection.
Daniel M Shafran, Stephen D Shafran

CMAJ· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.
Mark S Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki, Tarik Asselah, Jean-Michel Pawlotsky, Stephen D Shafran

Hepatology· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis